Trial Profile

ReConnection 2: phase 3 study of BPL-003 in patients with TRD

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 25 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 5 Methoxy N N Dimethyltryptamine (Primary)
Indications Treatment-resistant depressive disorder
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms ReConnection 2

Most Recent Events

12 May 2026 According to an Atai Beckley media release, Cash and cash equivalents as of March 31, 2026 expected to fund operations through anticipated BPL-003 Phase 3 topline readouts, with runway into 2029.
17 Mar 2026 According to an AtaiBeckley media release, the Phase 3 program for BPL-003 in TRD remains on track for initiation in Q2 2026.
12 Mar 2026 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com